# OnCo record gist-risk-stratification (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/gist-risk-stratification/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "gist-risk-stratification" ;
  schema:name "GIST risk stratification (mitotic count, size, site; Miettinen and modified NIH criteria)"@en ;
  schema:alternateName "Miettinen criteria"@en, "Miettinen risk"@en, "AFIP criteria"@en, "modified NIH criteria"@en, "Fletcher criteria"@en, "Joensuu criteria"@en, "GIST risk"@en, "GIST risk classification"@en, "mitotic count per 5 mm²"@en, "mitotic index in GIST"@en, "high-risk GIST"@en, "intermediate-risk GIST"@en, "low-risk GIST"@en, "very low risk GIST"@en, "tumour rupture in GIST"@en ;
  schema:description "Whether a gastrointestinal stromal tumour will come back after surgery is read from three things on the pathology report, its size, how many cells are dividing in a 5 square millimetre field, and where it started (stomach is safer than small bowel or rectum), plus whether it ruptured; high-risk patients get three years of imatinib and the others get none."@en ;
  schema:url <https://onco.cc/terms/gist-risk-stratification/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  onco:related <https://onco.cc/targets/kit/>, <https://onco.cc/targets/pdgfra/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/avapritinib/>, <https://onco.cc/terms/sdh-deficiency/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/tumour-grade/>, <https://onco.cc/terms/resection-margins/> ;
  onco:cancers <https://onco.cc/cancers/gist/>, <https://onco.cc/cancers/gist-kit-exon-11/>, <https://onco.cc/cancers/gist-pdgfra-d842v/>, <https://onco.cc/cancers/gist-imatinib-resistant/> .